FETID
发表于 2025-3-21 18:45:49
书目名称Chemotherapy for Leukemia影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0224970<br><br> <br><br>书目名称Chemotherapy for Leukemia读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0224970<br><br> <br><br>
Perineum
发表于 2025-3-21 21:25:20
http://reply.papertrans.cn/23/2250/224970/224970_2.png
有说服力
发表于 2025-3-22 01:20:32
Imatinib: Clinical Pharmacology and Therapeutic Resultsd with improved prognosis in several studies. Furthermore, approximately 40% of patients who exhibited sustained deep molecular response could maintain treatment-free remission after discontinuation of imatinib. Treatment-free remission is now considered to be a new goal of tyrosine kinase inhibitor
Malaise
发表于 2025-3-22 06:41:10
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsimab resistance in the treatment of chronic lymphocytic leukemia (CLL). The characteristic toxicities of rituximab are infusion reactions, late-onset neutropenia, hepatitis B virus reactivation, and opportunistic infections..Alemtuzumab is a humanized anti-CD52 mAb and the first mAb to be approved f
针叶类的树
发表于 2025-3-22 12:35:13
http://reply.papertrans.cn/23/2250/224970/224970_5.png
Generosity
发表于 2025-3-22 16:33:36
http://reply.papertrans.cn/23/2250/224970/224970_6.png
Generosity
发表于 2025-3-22 18:08:25
http://reply.papertrans.cn/23/2250/224970/224970_7.png
刺耳
发表于 2025-3-23 01:10:09
Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteney in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.
种子
发表于 2025-3-23 04:05:25
Nelarabinetravenous (IV) infusion given over 2 h on days 1, 3, and 5 and repeated every 21 days. In pediatric patients, the recommended dose is 650 mg/m. IV given over 1 h for five consecutive days and repeated every 21 days. In a large phase II study conducted by the German Multicenter Study Group for Adult
挖掘
发表于 2025-3-23 08:13:27
http://reply.papertrans.cn/23/2250/224970/224970_10.png